A 5-day regimen of cyclophosphamide, adriamycin, platinum (CAP) in refractory breast cancer
Fornasiero, A.; Daniele, O.; Aversa, S.M.; Ghiotto, C.; Morandi, P.; Fiorentino, M.V.
Chemioterapia International Journal of the Mediterranean Society of ChemoTherapy 6(4): 310-312
1987
ISSN/ISBN: 0392-906X PMID: 3652283 Document Number: 304231
The activity of the association of cis-platinum with Adriamycin and cyclophosphamide (CAP), as "rescue" chemotherapy for the treatment of refractory and relapsing advanced breast cancer, is presented. Of 42 evaluable patients, previously treated with chemotherapy +/- hormone therapy, 4 (9.5%) achieved a complete response, 15 (35%) had a partial response (CR + PR = 45%). Major toxicity observed was: nausea and vomiting in 95% of patients and leukopenia in 60%.
Document emailed within 1 workday
Related Documents
Taguchi, T.; Sakai, K.; Terasawa, T.; Wada, H. 1986: Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(9): 2820-2828Adam, Z.; Elbl, L.; Vorlícek, J.; Hájek, R.; Tomíska, M.; Hejlová, N.; Králová, E.; Novotná, H. 1994: Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD) Vnitrni Lekarstvi 40(8): 506-512
Abe, O.; Izuo, M.; Enomoto, K.; Kubo, K.; Koyama, H.; Sakai, K.; Terasawa, T.; Tominaga, T.; Nomura, Y. 1982: Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(5): 866-873
Abeloff, M.D.; Ettinger, D.S. 1977: Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy Cancer Treatment Reports 61(9): 1685-1689
Honda, S.; Toi, M.; Shimizu, S.; Hayashi, K.; Tominaga, T. 1997: The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(6): 679-683
Linasmita, V.; Wilailak, S.; Srisupundit, S.; Tangtrakul, S.; Bullangpoti, S.; Israngura, N. 1998: Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital Journal of the Medical Association of Thailand 81(1): 10-16
Wada, N.; Kobayashi, H.; Oka, S.; Ando, J.; Tamura, H. 2002: Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(11): 1935-1942
Tucker, J.D.; Wyrobek, A.J.; Ashworth, L.K.; Christensen, M.L.; Burton, G.V.; Carrano, A.V.; Everson, R.B. 1990: Induction, accumulation, and persistence of sister chromatid exchanges in women with breast cancer receiving cyclophosphamide, adriamycin, and 5-fluorouracil chemotherapy Cancer Research 50(16): 4951-4956
Ohara, N.; Teramoto, K. 2000: Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report Clinical and Experimental Obstetrics and Gynecology 27(2): 123-124
Ito, Y.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Mukaiyama, T.; Imajou, K.; Ozeki, H.; Nagamine, D.; Shinagawa, K. 1987: Combination chemotherapy with cis-platinum, vinblastine and adriamycin for non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(12): 3295-3300
Tangjitgamol, S.; Mamusirinitaya, S.; Leelahakorn, S.; Thawaramara, T.; Pataradool, K.; Suekwatana, P.; Sittidilokratna, K. 2005: Efficacy of platinum plus cyclophosphamide in patients with epithelial ovarian cancer Journal of the Medical Association of Thailand 88(9): 1172-1181
Ardizzoni, A.; Canobbio, L.; Pronzato, P.; Repetto, L.; Serrano, J.; Benvenuto, F.; Simonassi, C.; Baracco, F.; Faravelli, B.; Nosenzo, M. 1986: Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 5(6): 416-419
Abad-Esteve, A.; Rosell, R.; Moreno, I.; Fernández-Marcial, C.; Roselló, M.; Ribas Mundó, M. 1988: VP-16, vincristine, adriamycin and cyclophosphamide (EVAC) in patients with small-cell lung cancer Medicina Clinica 90(14): 569-572
Castiglione-Gertsch, M.; Tattersall, M.; Hacking, A.; Goldhirsch, A.; Gudgeon, A.; Gelber, R.D.; Lindtner, J.; Coates, A.; Collins, J.; Isley, M.; Senn, H.J.; Rudenstam, C.M. 1997: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group European Journal of Cancer 33(14): 2321-2325
Wilailak, S.; Tresukosol, D.; Linasmita, V.; Termrungruanglert, W. 2000: Phase Ii study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer European Journal of Gynaecological Oncology 21(6): 610-612
Einhorn, L.H.; Williams, S.D. 1978: Combination chemotherapy with cis-dichlorodiammineplatinum(II) and adriamycin for testicular cancer refractory to vinblastine plus bleomycin Cancer Treatment Reports 62(9): 1351-1353
Bilgi, O.; Karagoz, B.; Alacacioglu, A.; Ozgun, A.; Tuncel, T.; Gokhan-Kandemir, E. 2010: Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 15(2): 395
Hong, R.; Ma, F.; Shi, X.; Li, Q.; Zhang, P.; Yuan, P.; Wang, J.; Fan, Y.; Cai, R.; Li, Q.; Xu, B. 2014: Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs Zhonghua Zhong Liu Za Zhi 36(10): 788-792
Vogl, S.E.; Berenzweig, M.; Kaplan, B.H.; Moukhtar, M.; Bulkin, W. 1979: The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) Cancer Treatment Reports 63(2): 311-317
Scarfone, G.; Villa, A.; Parazzini, F.; Sciatta, C.; Polverino, G.; Bolis, G. 1999: A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy Tumori 85(4): 217-219